Sexy
Time
Three non-overlapping mechanisms. One spray. Desire from the brain down, blood flow from the body up, and bonding chemistry that makes everything more intense.
Three pathways.
One spray.
Most sexual wellness products target one thing — blood flow, or desire, or mood. Sexy Time works across three completely separate biological pathways simultaneously, none of which overlap or interfere with each other. PT-141 talks to the brain. Oxytocin talks to the limbic system. The PDE5 inhibitor talks to the vasculature. Together they cover every axis of the experience.
Activates MC3R and MC4R receptors in the hypothalamus — the brain regions that govern sexual motivation. It doesn't improve blood flow. It makes you want. This is a fundamentally different mechanism than any PDE5 inhibitor.
Quiets the amygdala, lowers cortisol, deepens trust and emotional connection. Intensifies orgasm — women reach 5× baseline oxytocin at climax. And it only works intranasally: GI enzymes destroy it completely before it can reach the brain.
Inhibits phosphodiesterase type 5, increasing cGMP and causing smooth muscle relaxation and vasodilation in genital tissue. Engorgement, sensitivity, and natural lubrication from increased blood flow.
Every ingredient, explained
PT-141 is a synthetic melanocortin peptide — a cyclic heptapeptide derived from alpha-MSH — that activates MC3R and MC4R receptors in the hypothalamus and limbic system. Unlike PDE5 inhibitors which work on blood vessels, PT-141 works on the central nervous system to generate genuine neurological arousal. It was originally developed by Palatin Technologies and later approved as Vyleesi for hypoactive sexual desire disorder in women. The intranasal route delivers it directly via the olfactory pathway.
Oxytocin is a nine-amino-acid neuropeptide produced in the hypothalamus and released by the posterior pituitary. It modulates social bonding, trust, stress response, and sexual function. Endogenous oxytocin rises dramatically during intimacy and peaks at orgasm — women reach approximately 5× baseline levels at climax. Exogenous intranasal oxytocin at 80 IU mimics this by activating central oxytocin receptors via the nose-to-brain pathway, lowering amygdala reactivity, reducing cortisol, and sensitizing the dopamine reward system. At 80 IU we're at the high end of the clinically studied range, matching real-world reports of optimal experiential effect.
Sildenafil inhibits phosphodiesterase type 5, preventing the breakdown of cGMP in smooth muscle cells. Elevated cGMP causes smooth muscle relaxation and vasodilation — in genital tissue, this means increased blood flow, engorgement, and sensitivity. In women, sildenafil increases clitoral blood flow and engorgement; women's formula uses a higher dose (20mg vs 10mg in the men's) because there's no tadalafil coverage. Intranasal sildenafil has approximately 112.9% relative bioavailability versus oral — meaning 20mg nasal is equivalent to roughly 22mg oral, achieving meaningful plasma levels without the full systemic load of a standard 50–100mg oral tablet.
Tadalafil is a long-acting PDE5 inhibitor with a half-life of 17.5 hours and an effective coverage window of up to 36 hours — marketed as Cialis. Where sildenafil covers the immediate window (4–6 hours), tadalafil provides the sustained background vasodilation that makes the morning-after experience as covered as the initial window. The combination of fast-onset sildenafil plus long-acting tadalafil in a single spray is a genuinely differentiated approach — one dose covers both the moment and the next day. At 10mg each, both PDE5 inhibitors stay well below maximum clinical doses while producing additive effect.
Choose your formula
Same three-pathway architecture. Different balance — women's doubles the sildenafil since there's no tadalafil coverage. Men's adds tadalafil for 36-hour duration. Both deliver the same PT-141 and oxytocin dose.
Higher sildenafil dose (20mg) since there's no tadalafil in the formula. Women's anatomy responds differently to PDE5 inhibition — increased clitoral engorgement, sensitivity, and natural lubrication.
Dual PDE5 inhibition — sildenafil for fast onset, tadalafil for 36-hour coverage. Lower individual doses (10mg each) producing additive effect without maxing either compound. Four actives, same cost as women's formula.
Dosing & timing
Apply 3 sprays — 1–2 per nostril. PT-141 needs time to reach the hypothalamus and produce CNS arousal. Don't spray and expect instant results.
3 × 0.11mL = 0.33mL total. Alternate nostrils or 2 in one, 1 in the other. Inhale gently while spraying — don't snort hard.
5mL fill at 0.33mL per dose = exactly 15 doses. Refrigerate between uses at 2–8°C. BUD 30 days from preparation.
Store refrigerated 2–8°C. Let warm slightly before use — cold spray can be uncomfortable. Do not freeze.
Why intranasal changes everything
The nasal route isn't a workaround — for these specific compounds, it's the superior delivery method. Not just faster. Fundamentally different.
GI enzymes completely destroy oxytocin before it reaches the bloodstream. Sublingual troches, oral capsules — all inactive. The only non-injection route that delivers active oxytocin to the CNS is intranasal, via the olfactory nerve pathway directly into the brain.
Olfactory and trigeminal nerves run from the nasal cavity directly into the CNS — bypassing the blood-brain barrier. For a peptide targeting the hypothalamus, this is a more direct route than subcutaneous injection, which must reach the hypothalamus via systemic circulation.
Intranasal sildenafil has ~112.9% relative bioavailability compared to oral — more of the dose reaches circulation because it bypasses first-pass hepatic metabolism. 20mg nasal is pharmacologically equivalent to roughly 22mg oral, while the systemic load is lower.
Oral medications require gastric absorption, portal vein transit, hepatic processing, and systemic distribution — typically 30–90 minutes. Nasal absorption goes directly into the bloodstream from the mucosa in minutes. The difference between planning sex and responding to the moment.